Biomaterial Database

Levocabastine nasal spray significantly improves perennial allergic rhinitis: a single-blind placebo-controlled study. 2010

Kimihiro Okubo, and Eiji Uchida, and Shoji Nogami

Department of Otolaryngology, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan. ent-kimi@nms.ac.jp

OBJECTIVE The efficacy of levocabastine nasal spray for relieving the symptoms of perennial allergic rhinitis was compared with placebo in a single-blind study. METHODS Three hundred and thirty-five patients with moderate to severe perennial allergic rhinitis were randomized to three groups that were administered a high or low dose of levocabastine nasal spray or a placebo. Patients were not informed of their treatment. Efficacy was evaluated based on the changes of symptoms and rhinoscopy findings. RESULTS Significant improvement of symptoms was observed in both the high-dose and low-dose levocabastine groups compared with the placebo group. There were no significant differences of efficacy between the high-dose and low-dose levocabastine groups. There was also no significant difference in the occurrence of adverse effects among the three groups. CONCLUSIONS Levocabastine nasal spray is a safe and effective treatment for perennial allergic rhinitis.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281	Administration, Intranasal	Delivery of medications through the nasal mucosa.	Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D012221	Rhinitis, Allergic, Perennial	Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc.	Rhinitis, Allergic, Nonseasonal
D015508	Nasal Obstruction	Any hindrance to the passage of air into and out of the nose. The obstruction may be unilateral or bilateral, and may involve any part of the NASAL CAVITY.	Bilateral Nasal Obstruction,Nasal Airway Obstruction,Nasal Blockage,Unilateral Nasal Obstruction,Airway Obstruction, Nasal,Blockage, Nasal,Blockages, Nasal,Nasal Blockages,Nasal Obstruction, Bilateral,Nasal Obstruction, Unilateral,Obstruction, Bilateral Nasal,Obstruction, Nasal,Obstruction, Nasal Airway,Obstructions, Nasal
D016037	Single-Blind Method	A method in which either the observer(s) or the subject(s) is kept ignorant of the group to which the subjects are assigned.	Single-Masked Study,Single-Blind Study,Single-Masked Method,Method, Single-Blind,Method, Single-Masked,Methods, Single-Blind,Methods, Single-Masked,Single Blind Method,Single Blind Study,Single Masked Method,Single Masked Study,Single-Blind Methods,Single-Blind Studies,Single-Masked Methods,Single-Masked Studies,Studies, Single-Blind,Studies, Single-Masked,Study, Single-Blind,Study, Single-Masked
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D039563	Histamine H1 Antagonists, Non-Sedating	A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment.	Second Generation Antihistamine,Second Generation H1 Antagonist,Third Generation H1 Antagonist,H1 Antihistamines, Non-Sedating,Second Generation Antihistamines,Second Generation H1 Antagonists,Third Generation H1 Antagonists,Antihistamine, Second Generation,Antihistamines, Second Generation,Generation Antihistamine, Second,H1 Antihistamines, Non Sedating,Histamine H1 Antagonists, Non Sedating,Non-Sedating H1 Antihistamines